Legrand announces the publication of a study showing that Indigo-Clean Light technology safely and effectively kills SARS-CoV-2 and influenza A viruses

KENOSHA, Wisconsin., September 30, 2021 / PRNewswire / – Legrand today announced the publication of a study showing its Indigo-Clean® light disinfection technology safely and effectively inactivates SARS-CoV-2 and influenza A viruses in a range of actual clinical settings. This evidence, published in partnership with the Icahn School of Medicine at Mount Sinai, reinforces the utility of Indigo-Clean as an innovative medical technology tool that continually helps hospitals keep frontline workers and patients safe while providing urgent, high-quality care.

The article, “Virucidal effects of visible light at 405 nm on SARS-CoV-2 and influenza A virus”, was published in Scientific reports to September 30, 2021. It reflects how the researchers assessed the rate of inactivation of the SARS-CoV-2 virus using visible light at 405 nm under a range of clinical conditions. Kenall then applied these results to a real-world usage model and determined that Indigo-Clean would achieve a SARS-CoV-2 inactivation rate of 94% based on 12 hours of room use. occupied and 12 hours of use of the unoccupied room. The study was funded by Kenall.

“The results of this research are of critical importance as the COVID-19 pandemic continues, the flu season approaches and hospitals face increasing pressure to use all available spaces to provide care. “, said Yahnke Cliff, Ph.D., Chief Scientist and Head of Clinical Affairs at Kenall. “Already proven to kill harmful bacteria, such as staph and MRSA, Indigo-Clean can be integrated into any healthcare system’s mitigation strategy to help prevent infections, leading to better patient health outcomes and delivering return on investment in as little as 2.2 months.

The potential for specific wavelengths in the electromagnetic spectrum is an area of ​​growing clinical interest. Ultraviolet (UV) technologies have demonstrated their ability to reduce virological spread, but potential toxicities have limited their use in occupied spaces. Longer wavelengths with less irradiation energy such as visible light (405 nanometers) have been widely evaluated in bactericidal and fungicidal applications. This research offers some of the strongest evidence to date of the real-world application of 405nm visible light to inactivate SARS-CoV-2 and influenza A viruses, helping to create safe and secure spaces. busy.

“It is essential to reduce the ability of SARS-CoV-2 and influenza A to spread in healthcare facilities,” said Adolfo Garcia-Sastre, Ph.D., director of the Global Health & Emerging Pathogens Institute and professor of microbiology and medicine at the Icahn School of Medicine in Mount Sinai and the principal investigator of the study. “This research adds important results to the medical literature. It shows the potential of a simple and non-invasive technological solution to achieve inactivation of these highly disruptive viruses and warrants further evaluation in a range of additional clinical parameters to further validate its efficacy and safety. . “

ABOUT INDIGO-CLEAN
Indigo-Clean is a registered trademark of Kenall Manufacturing Co., a Legrand company. Indigo-Clean® is a patented technology that is easily installed in overhead lighting to safely, automatically and continuously disinfect air and hard and soft surfaces.

Kenall was founded in Chicago, Illinois in 1963 and has built a reputation for sustainable lighting solutions of superior quality and exceptional value. Today, the company creates unique solutions for the healthcare, cleanroom / containment, food processing, transportation, high abuse and correctional lighting markets. Kenall fixtures are designed in Kenosha, Wisconsin, and comply with the Buy American Act (made in United States with more than 50% of the cost of components of American origin).

ABOUT LEGRAND
Legrand is the world specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for the commercial, industrial and residential markets makes it a benchmark for customers around the world. The Group exploits technological and societal trends having lasting impacts on buildings with the aim of improving life by transforming living, working and meeting spaces with electrical, digital infrastructures and simple, innovative and sustainable connected solutions. . Based on an approach involving all teams and stakeholders, Legrand is pursuing its strategy of profitable and sustainable growth driven by acquisitions and innovation, with a constant flow of new offers, including Eliot connected products with use value reinforced. Legrand generated sales of 6.1 billion euros in 2020. The company is listed on Euronext Paris and is notably part of the CAC 40 and CAC 40 ESG indices (ISIN code FR0010307819). https://legrandgroup.com

About the Mount Sinai Health System
The Mount Sinai health system is that of New York largest university medical system, encompassing eight hospitals, a leading medical school and an extensive network of outpatient practices in the greater new York Region. We advance medicine and health through unparalleled education and translational research and discovery to provide the safest, highest quality, most accessible and equitable care, and the best value of any healthcare system. health of the country. The health system includes around 7,300 primary and specialist care physicians; 13 independent joint venture centers; more than 410 outpatient clinics in the five arrondissements of New York City, Westchester, and Long island; and over 30 affiliated community health centers. Mount Sinai Hospital is classified in US News and World Reports Honor Roll of the 20 best American hospitals and among the best in the country by specialty: n ° 1 in geriatrics and top 20 in cardiology / cardiac surgery, diabetes / endocrinology, gastroenterology / gastrointestinal surgery, neurology / neurosurgery, orthopedics , pneumology / Pulmonary surgery, urology and rehabilitation. Mount Sinai Kravis Children’s Hospital is classified under US News and World Reports “Best Children’s Hospitals” among the best in the country in four of the ten pediatric specialties. New York Eye and Ear Infirmary Mount Sinai is ranked among the top 20 nationally for ophthalmology. Icahn School of Medicine in Mount Sinai is one of the three faculties of medicine that have distinguished themselves by several indicators: ranked among the top 20 by US News and World Reports “Best medical schools”, aligned with a American News and World Report Honor Roll Hospital and No. 14 in the country for funding from the National Institutes of Health. News week“World’s Best Smart Hospitals” Ranks Mount Sinai Hospital # 1 new York and among the top five in the world, and Mount Sinai Morningside among the top 20 in the world, and “The World’s Best Specialty Hospitals” ranks Mount Sinai Heart as No. 1 in new York and # 5 globally and the Division of Gastroenterology # 5 globally. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

SOURCE Legrand

Related links

http://legrandgroup.com



Source link

Paul N. Strickland